Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
|Podcasts|February 8, 2023
Expert Training from PDA: An Investment in Your Future
Author(s)PDA
Built on a reputation of excellence and founded in science, PDA training provides new and experienced professionals around the world with practical information and implementable solutions on essential industry topics related to the manufacturing science, regulation, and technology of drug products and substances. Our trainers are world-class experts with years of hands-on experience in their respective fields. Whether you are employed in industry, government, or academia, PDA has training that will benefit you!
Related to this article
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
5